Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. Read more about Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer. Read more about Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer.
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Read more about Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. Read more about RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Meeting Exercise Recommendations Is Beneficial for Cancer Survivors. Read more about Meeting Exercise Recommendations Is Beneficial for Cancer Survivors.
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. Read more about Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline. Read more about Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline.
Systemic Therapy for Melanoma: ASCO Guideline Update. Read more about Systemic Therapy for Melanoma: ASCO Guideline Update.
Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma. Read more about Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. Read more about Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
